Adaptimmune Therapeutics Plc, a commercial-stage cell therapy company based in Abingdon, Oxfordshire, focuses on novel T-cell therapies for cancer, including afamitresgene autoleucel and Lete-cel. The company employs 449 people and went public on May 6, 2015.